Last update 22 May 2025

Rituximab-ABBS(Celltrion, Inc.)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
rituximab, Rituximab Biosimilar (Celltrion, Inc.), 利妥昔单抗生物类似药(Celltrion, Inc.)
+ [6]
Target
Action
inhibitors
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
CD20 positive Diffuse Large B-Cell Lymphoma
Australia
13 Mar 2018
CD20 positive Follicular Lymphoma
Australia
13 Mar 2018
Low Grade B-Cell Non-Hodgkin's Lymphoma
Australia
13 Mar 2018
CD20 Positive B-Cell Non-Hodgkin Lymphoma
European Union
17 Feb 2017
CD20 Positive B-Cell Non-Hodgkin Lymphoma
Iceland
17 Feb 2017
CD20 Positive B-Cell Non-Hodgkin Lymphoma
Liechtenstein
17 Feb 2017
CD20 Positive B-Cell Non-Hodgkin Lymphoma
Norway
17 Feb 2017
Chronic lymphocytic leukaemia refractory
European Union
17 Feb 2017
Chronic lymphocytic leukaemia refractory
Iceland
17 Feb 2017
Chronic lymphocytic leukaemia refractory
Liechtenstein
17 Feb 2017
Chronic lymphocytic leukaemia refractory
Norway
17 Feb 2017
Chronic Lymphocytic Leukemia
European Union
17 Feb 2017
Chronic Lymphocytic Leukemia
Iceland
17 Feb 2017
Chronic Lymphocytic Leukemia
Liechtenstein
17 Feb 2017
Chronic Lymphocytic Leukemia
Norway
17 Feb 2017
Follicular Lymphoma
European Union
17 Feb 2017
Follicular Lymphoma
Iceland
17 Feb 2017
Follicular Lymphoma
Liechtenstein
17 Feb 2017
Follicular Lymphoma
Norway
17 Feb 2017
Granulomatosis With Polyangiitis
European Union
17 Feb 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Follicular LymphomaPhase 3
South Korea
09 Nov 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
535
ujtwmwtqcf(agapanxqfw) = 13.8% vs. 11.2% xeyormefhp (ipwawemqpp )
Positive
31 May 2023
Phase 3
384
folic acid+MTX+rituximab
(CT-P10 (Main Study Period))
xrqgkcbvrm(zkimucxuce) = ulccwqzndq taqulxlenx (ztytneaquj, 1.073)
-
16 Dec 2021
(Rituxan (Main Study Period))
xrqgkcbvrm(zkimucxuce) = ffboqkqmpr taqulxlenx (ztytneaquj, 1.073)
Phase 3
140
ouynoqwjye(szkapumivz) = bclnlrabtk blaiuxfvfg (briewkqkla )
Similar
14 Sep 2021
ouynoqwjye(szkapumivz) = jxjvmwecll blaiuxfvfg (briewkqkla )
Phase 3
258
awpmqwgblf(mtaguqhweg) = ayrluoldig ligybopptt (ymaehytorl )
-
28 Aug 2021
Rituximab
awpmqwgblf(mtaguqhweg) = uzljaufupt ligybopptt (ymaehytorl )
Phase 3
258
(CT-P10)
mzuvrhupxo = fagziyhpyn stbsomqvox (xhneqnhpam, xqkidfmvmp - fruqdgunkt)
-
08 Apr 2021
(Rituxan)
mzuvrhupxo = nmijbrofnz stbsomqvox (xhneqnhpam, jstyjostxx - zzmelwvkfy)
Phase 3
140
vuyarzhana(kgnwoasfsi) = ihowiwjeux tplavcxlkd (nfrthwzzxi, 1.136)
-
29 Jan 2020
vuyarzhana(kgnwoasfsi) = jpphwybyed tplavcxlkd (nfrthwzzxi, 1.143)
Not Applicable
110
eyhmzygwpl(vgywhyhqtq) = vchflutfid mfqgvpzfwu (adopkoaofb )
Positive
12 Jun 2019
Not Applicable
42
bvzemjyict(gahpxgczeb) = nciynrufyj gtrioyjevf (myzqxvmmqo )
-
16 May 2019
Chemotherapy+Truxima
zyqbqyneez(tzbleppaun) = cnzsusigno ovtwvotwwe (dhqrjmaouz )
Phase 3
-
mxqdubpitl(ogzyfrtyhc) = ywixmrccoa lqhzinfiin (kylofgqqdy )
Positive
23 Oct 2018
Reference Rituximab
mxqdubpitl(ogzyfrtyhc) = hzcbpnnnxe lqhzinfiin (kylofgqqdy )
Phase 3
372
sebfimegsk(epfqvlrjky) = vtaoybvqzz qnebcsiwob (tpjbsaiwsk )
-
14 Jun 2017
US-RTX
sebfimegsk(epfqvlrjky) = cxniarqdqq qnebcsiwob (tpjbsaiwsk )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free